Navigation Links
Prenatal whole genome sequencing: Just because we can, should we?
Date:8/10/2012

(Garrison, NY) With whole genome sequencing quickly becoming more affordable and accessible, we need to pay more attention to the massive amount of information it will deliver to parents and the fact that we don't yet understand what most of it means, concludes an article in the Hastings Center Report. The authors are current or former scholars at the National Institutes of Health's Department of Bioethics.

Most analyses of the ethical issues raised by whole genome sequencing have been "futuristic forecasting," but the authors conclude that "this is problematic given the speed with which whole genome sequencing is likely to be incorporated into clinical care," as its price falls to under $1,000.

Prenatal whole genome sequencing differs from current prenatal genetic testing practice in ethically relevant ways. Most notably, whole genome sequencing would radically increase the volume and scope of available prenatal genetic data. In contrast with current tests, which identify serious genetic conditions in fetuses at high risk of them, the new tests would likely be used by many more expectant parents and reveal a wide spectrum of genetic traits, including disease susceptibility.

Some of the ethical challenges posed by prenatal whole genome sequencing arise from the uncertainty of what the information means. The function of more than 90 percent of genes in the human genome is unknown and as a result, the article says, "much of the data generated from whole genome sequencing over the next few years (or even decades) will be of questionable utility."

After analyzing the kind of information that whole genome prenatal testing will yield, the authors conclude that most of it would probably not be as helpful as information uncovered by the current categories of prenatal tests. They cited specific areas of concern.

First of all, the quality and quantity of information may augment parents' anxiety. "To the extent that parents now think of their child as a 'clean slate' during pregnancy, the prenatal image of a normal, healthy baby will be dramatically altered by this technology," the authors write. The anxiety over the results and changing views of what is "normal" could lead to an increase in pregnancy terminations.

Apart from reproductive decisions, the authors also foresee whole genome prenatal testing having a negative impact on child rearing. For example, if parents were able to get genetic information suggesting that their child's predicted IQ may be low, they might not strongly encourage and support the child's efforts in school.

Finally, the new technology could increase the tension between the interests of parents and children. Although parents have a strong interest in getting information that informs their reproductive choices, children have a competing interest in not knowing certain kinds of information about themselves information that could limit their autonomy as they grow into adulthood.

Given the potential harms from prenatal whole genome sequencing, the authors make four preliminary recommendations.

  • Since only some of the information will be relevant to most parents' reproductive decision-making, the medical community should make clear recommendations about which categories of information should be routinely offered to parents.

  • A child's right "not to know" his or her genetic information should not be breached unless the information is clearly useful for the parents or can improve health outcomes in the child. "We recommend that the relevant societies revise their prenatal testing guidelines to ensure that their recommendations are sufficient and appropriate for the next generation of sequencing technologies."

  • More data are needed to guide the deliberation of professional societies and the public.

  • Professional societies should play an active role in educating clinicians on how whole genome sequencing differs from traditional prenatal genetic tests, and on how to educate parents about the tradeoffs involved in choosing to engage in it.


'/>"/>

Contact: Susan Gilbert
gilberts@thehastingscenter.org
845-424-4040 x244
The Hastings Center
Source:Eurekalert

Related biology news :

1. Prenatal exposure to air pollution linked to childhood obesity
2. Prenatal micronutrient, food supplementation intervention in Bangladesh decreases child death rate
3. Cod has a key role in the whole Baltic Sea
4. Leading evolutionary scientist to discuss how genome of bacteria has evolved
5. Darwin in the genome
6. Analysis of stickleback genome sequence catches evolution in action
7. Athletic frogs have faster-changing genomes
8. PNAS: Precise molecular surgery in the plant genome
9. BGI and Aspera collaborate on high-speed data exchange to advance genome research
10. Researchers announce GenomeSpace environment to connect genomic tools
11. UC Santa Cruz builds national data center for cancer genome research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Dec. 5, 2016  The Office of Justice ... "Can CT Scans Enhance or Replace Medico Legal ... of supporting or replacing forensic autopsies with postmortem ... In response to recommendations made by ... using CT scans as a potential component of ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH llc ... partnership initiative targeting national brands, industry thought-leaders and ... their respective audiences for taking steps to live ... inception in 2012, higi has built the largest ... over 38 million people who have conducted over ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. ... biopharmaceutical company focused on developing and commercializing products ... unmet medical need, announced today the long-term follow-up ... SGX942 (dusquetide), a first-in-class Innate Defense Regulator (IDR), ... head and neck cancer patients undergoing chemoradiation therapy ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/8/2016)... 2016 Eutilex Co. Ltd. today announced that ... Series A financing. This financing round included participation from ... SNU Bio Angel. This new funding brings the total ... $27.7M) since its founding in 2015. ... and commercialization of its immuno-oncology programs, expand its R&D ...
(Date:12/8/2016)... Dec. 8, 2016   Biocept, Inc . ... provider of clinically actionable liquid biopsy tests to ... clinical data featuring its Target Selectorâ„¢ Circulating Tumor ... for the detection of actionable biomarkers in patients ... sponsored by Sara Cannon Research Institute (SCRI), the ...
Breaking Biology Technology: